Cleveland‑Cliffs signed a three‑year deal with Palantir to bring AI into production planning and order workflows across its mills, a move that promises efficiency and raises local questions.

An Ohio University analysis of Cirque du Soleil medical records found 354 concussions across 2.7 million exposures — about 1.3 per 10,000 — lower than many expect.

Case Western Reserve landed a $3.1M NICHD grant to test three ways to restore touch in people with quadriplegia. The trial will use volunteers already implanted with electrodes.

Case Western Reserve tapped Susan Hagness, a UW–Madison electrical engineer, as the Case School of Engineering's first woman dean; she starts July 1, 2026.

Cleveland Fire demoed F-500, a water additive for lithium‑ion and metal fires, and said crews will carry it in 5‑gallon tanks on every rig.

An Oakwood Village woman says a Cleveland Clinic gene‑editing trial has cut years of sickle‑cell pain and hospital visits. Early results from the RUBY study show promising improvements for participants.

An Ohio State study using objective lab tests of 60 adults finds long COVID often causes measurable smell, hearing, balance and cognitive problems, with age and severe illness linked to worse outcomes.

A NEJM‑published LATITUDE trial shows monthly cabotegravir‑rilpivirine injections reduced regimen failures among people who struggle with daily oral HIV therapy. University of Cincinnati clinicians were among the lead sites.

Researchers at Case Western and MetroHealth developed CD133‑targeted RNA nanoparticles that silence the FTO gene and slowed drug‑resistant leukemia in lab models.

Cleveland Clinic reassigned senior leaders to centralize oversight of international affiliates and partnerships as it moves to scale care and services abroad.

Ohio University researchers report pegvisomant (Somavert) restored chemo sensitivity in lab models of non‑small cell lung cancer, animal and clinical tests are next.

An Ohio State randomized trial found adding a stellate ganglion block to therapy produced fast, durable drops in veterans' PTSD symptoms. The nerve block sped recovery in many participants.

Stanford and other U.S. hospitals are testing CAR‑T as a one‑time treatment for progressive MS. Early data show immune effects but safety and repair of old damage remain uncertain.